The Power of Targeted Protein Degradation (TPD) and How It Could Redefine the Hepatocellular Carcinoma (HCC) Treatment Paradigm

Captor Therapeutics’ leadership team will discuss how their broadly applicable Optigrade™ platform allows for the sustainable creation and discovery of TPD drugs.

The event will also feature a presentation from Key Opinion Leader Thomas F. Baumert, MD (University of Strasbourg), who will discuss the unmet medical need in hepatocellular carcinoma. Dr. Baumert will speak to the current landscape of HCC drugs and how Captor’s CT-01 program could lead to a paradigm shift in how HCC patients are treated.

A live question and answer session will follow.